Proteros biostructures GmbH today announced that Rodin Therapeutics, Inc., a Boston, MA based biotech company developing novel, small molecule therapeutics for synaptopathies has been acquired by Alkermes plc, a global biopharmaceutical company headquartered in Dublin, Ireland. Rodin has been co-founded by Proteros in 2013. Rodin’s security holders will receive an upfront payment of $100 million plus milestone payments.
Source: BioSpace